Teva, Boehringer Slapped With New Pay-For-Delay Suit

Law360, Los Angeles (January 24, 2014, 6:03 PM EST) -- Teva Pharmaceuticals Inc. and Boehringer Ingelheim Pharmaceuticals Inc. were slapped on Friday with another proposed class action, this one in Pennsylvania federal court, over an alleged $120 million deal to delay the entry into the market of a generic version of a stroke-prevention medication.

A health and welfare fund for the National Electrical Contractors Association and the International Brotherhood of Electrical Workers claimed in a class action complaint that a pay-for-delay agreement between Boehringer and Teva subsidiary Barr Pharmaceuticals Inc. has caused indirect purchasers of Boehringer's...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.